


CK-636

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-15892 | | |
| CAS No.: | 442632-72-6 | | |
| Molecular Formula: | C ₁₆ H ₁₆ N ₂ OS | | |
| Molecular Weight: | 284.38 | | |
| Target: | Arp2/3 Complex | | |
| Pathway: | Cytoskeleton | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 49 mg/mL (172.30 mM)
 H₂O : < 0.1 mg/mL (insoluble)
 * "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent | | Mass | | |
|---------------------------|---------------|--|-----------|------------|------------|
| | Concentration | | 1 mg | 5 mg | 10 mg |
| | 1 mM | | 3.5164 mL | 17.5821 mL | 35.1642 mL |
| | 5 mM | | 0.7033 mL | 3.5164 mL | 7.0328 mL |
| | 10 mM | | 0.3516 mL | 1.7582 mL | 3.5164 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.5 mg/mL (8.79 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CK-636 is a cell permeable inhibitor of Arp2/3 complex, that could inhibit actin polymerization, with IC₅₀ values of 4 μM, 24 μM and 32 μM for human, fission yeast and bovine, respectively.

IC₅₀ & Target

IC₅₀: 4/24/32 μM (Human/fission yeast/bovine Arp2/3)^[1].

In Vitro

CK-636 binds between Arp2 and Arp3, where it appears to block movement of Arp2 and Arp3 into their active conformation. CK-636 inserts into the hydrophobic core of Arp3 and alters its conformation. CK-636 prevents actin polymerization and the formation of actin filament comet tails by *Listeria* in infected SKOV3 cells ($IC_{50}=22 \mu M$)^[1]. Additionally, CK-636-treated T cells exhibits elongated morphology with sharp pseudopodia at the leading edges, while the breadth of the CK-636-treated T cells is about 30% less than that of DMSO-treated T cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Nolen BJ, et al. Characterization of two classes of small molecule inhibitors of Arp2/3 complex. *Nature*. 2009 Aug 20;460(7258):1031-4.

[2]. Kwon KW, et al. Migration of T cells on surfaces containing complex nanotopography. *PLoS One*. 2013 Sep 12;8(9):e73960.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA